


Product Name : DBPR728
Cat. No. : PC-22141
CAS No. : 2702965-64-6
Molecular Formula : C₂₉H₃₇ClFN₉O₂
Molecular Weight : 598.12
Target : Aurora Kinase
Solubility : 10 mM in DMSO



CAS: 2702965-64-6

Biological Activity

DBPR728 is an oral bioavailable acyl-based prodrug of **6K465**, which is a potent selective **Aurora A** (AURKA) inhibitor, effectively inhibits cancer cells overexpressing c-MYC- and/or N-MYC.

DBPR728 induced durable tumor regression of c-MYC- and/or N-MYC- overexpressing xenografts including SCLC, triple-negative breast cancer (TNBC), hepatocellular carcinoma and medulloblastoma.

DBPR728 at 300 mg/kg induced c-MYC reduction and cell apoptosis in the tumor xenografts for more than 7 days.

DBPR728 also synergized with the mTOR inhibitor everolimus to suppress c-MYC- or N-MYC- driven SCLC.

References

Chang CP, et al. *Mol Cancer Ther.* 2024 Apr 9. doi: 10.1158/1535-7163.MCT-23-0602.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com